Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $2.1 million.

  • Viking Therapeutics' Change in Accured Expenses rose 12636.55% to $2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.2 million, marking a year-over-year increase of 605.23%. This contributed to the annual value of $6.2 million for FY2025, which is 605.23% up from last year.
  • Latest data reveals that Viking Therapeutics reported Change in Accured Expenses of $2.1 million as of Q4 2025, which was up 12636.55% from -$4.8 million recorded in Q3 2025.
  • Over the past 5 years, Viking Therapeutics' Change in Accured Expenses peaked at $15.9 million during Q1 2024, and registered a low of -$13.6 million during Q2 2024.
  • Over the past 5 years, Viking Therapeutics' median Change in Accured Expenses value was $250500.0 (recorded in 2021), while the average stood at $773550.0.
  • In the last 5 years, Viking Therapeutics' Change in Accured Expenses crashed by 86271.51% in 2023 and then soared by 647288.14% in 2024.
  • Over the past 5 years, Viking Therapeutics' Change in Accured Expenses (Quarter) stood at -$1.1 million in 2021, then skyrocketed by 330.71% to $2.5 million in 2022, then soared by 57.26% to $3.9 million in 2023, then plummeted by 299.8% to -$7.8 million in 2024, then surged by 126.37% to $2.1 million in 2025.
  • Its Change in Accured Expenses was $2.1 million in Q4 2025, compared to -$4.8 million in Q3 2025 and $14.6 million in Q2 2025.